Ambrx Biopharma (AMAM) Stock Price, News & Analysis

Company Overview

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Key Stats

• Today's Range: $28.00 to $28.00
• 50-Day Range: $27.70 to $28.00
• 52-Week Range: $6.55 to $28.15
• Volume: N/A
• Average Volume: 2.12 million shs
• Market Capitalization: $1.77 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.00
• Consensus Rating: Hold

Ambrx Biopharma Stock Analysis - MarketRank™

Ambrx Biopharma scored higher than 5% of companies evaluated by MarketBeat, and ranked 925th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

Ambrx Biopharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ambrx Biopharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ambrx Biopharma are expected to grow in the coming year, from ($1.45) to ($1.28) per share.

Price to Book Value per Share Ratio

Ambrx Biopharma has a P/B Ratio of 9.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AMAM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ambrx Biopharma does not currently pay a dividend.

Dividend Growth

Ambrx Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for AMAM.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

24 people have searched for AMAM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ambrx Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.64% of the stock of Ambrx Biopharma is held by insiders.

Percentage Held by Institutions

77.28% of the stock of Ambrx Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AMAM Stock Analysis - Frequently Asked Questions

When did Ambrx Biopharma IPO?

Ambrx Biopharma (AMAM) raised $126 million in an IPO on Friday, June 18th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen served as the underwriters for the IPO.

What other stocks do shareholders of Ambrx Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ambrx Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Adobe (ADBE).

Company Calendar

• Today: 12/23/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NYSE:AMAM
• CUSIP: N/A
• CIK: 1836056
• Web: ambrx.com
• Phone: 858-875-2400
• Fax: N/A
• Employees: 87
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $28.00
• High Stock Price Target: $28.00
• Low Stock Price Target: $28.00
• Potential Upside/Downside: 0.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.28
• Quick Ratio: 13.28

Sales & Book Value

• Annual Sales: $7.40 million
• Price / Sales: 238.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.05 per share
• Price / Book: 9.18

Miscellaneous

• Outstanding Shares: 63,150,000
• Free Float: 62,746,000
• Market Cap: $1.77 billion
• Optionable: Optionable
• Beta: -1.92